The FDA declined to comment specifically on the Bupropion sr dosage
Early response to treatment with Empatic predicted greater weight loss at weeks. The Contrave clinical trial showed improvements in risk factors associated with metabolic syndrome including triglycerides, HDL good cholesterol, waist circumference, insulin and fasting glucose. The most significant improvements were found in patients with higher levels of baseline insulin or triglycerides.
These forward looking statements include statements regarding the enrollment, timing, execution and completion of clinical trials of its product candidates, the timing of an NDA Similac advanced baby formula for Contrave, the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave and Empatic, and the scope and duration of protection of issued patents relating to the Company’s product candidates. For those having problems, please hit your refresh button. Results based on a modified ITT analysis show. Early response to treatment with Empatic predicted greater weight loss.